Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis

Résumé

Targeted axillary dissection (TAD) is an innovative approach for axillary staging in breast cancer patients with initially node-positive disease that converts to clinically node-negative status after neoadjuvant therapy. Optimal marking and localization techniques remain undetermined. This systematic review and meta-analysis searched PubMed, Scopus, Cochrane Library, and Web of Science through April 2025, including 59 observational studies on TAD (marked/clipped node removal plus sentinel lymph node biopsy) in such patients. Primary outcomes were identification rate, false-negative rate (FNR), concordance, and diagnostic accuracy. Using R software with random-effects models and logit transformation, TAD achieved a pooled identification rate of 95.1% (95% CI: 93.2%-96.5%). Pooled FNR was 6.37% (95% CI: 5.02%-8.04%; I² = 0.0%), with overall diagnostic accuracy of 94.68% (95% CI: 91.70%-96.63%). Targeted and sentinel nodes concorded in 73.34% (95% CI: 69.58%-76.79%). Subgroup analyses showed comparable performance across marking (clip, carbon, magnetic, radioactive seeds) and localization techniques (wire-guided, radioactive, magnetic, ultrasound-guided), with no significant differences. TAD offers high identification rates, low FNRs, reliable staging, and acceptable accuracy, with consistent results enabling implementation using locally available technologies.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0